Public consultation response to WP5 Strand B’s draft project plan
Public Consultation replies_from_authors_for publication.pdf
1st pilot rapid assessment of WP5 JA2 Strand B on “Duodenal-jejunal bypass sleeve for the treatment of obesity with or without Type II Diabetes Mellitus”
The purpose of the assessment is to examine the effectiveness and safety of the duodenal-jejunal bypass sleeve/EndoBarrier® in in adults aged 18 years or older with grade II or III obesity (with comorbidities) and/or type 2 diabetes mellitus (+ obesity ≥ grade I) who are not adequately controlled with medication (oral and/or insulin) and lifestyle […]
The first pilot rapid assessment on ‘Zostavax for the prevention herpes zoster’
The purpose of the assessment is to evaluate Zostavax® for the prevention of herpes zoster. Final version of the assessment was published in September 2013 Below is the documentation provided by the Joint Assessment authoring team: Zostavax for prevention of herpes zoster and postherpetic neuralgia_Rapid REA_Final_Sep 2013_0.pdf
EUnetHTA Joint Action 2 3-year Work plan (2013)
The EUnetHTA Joint Action 2 3-Year Work Plan lays out details and timelines of the activities planned in each of the eight Work Packages of EUnetHTA JA2 and guides the work of EUnetHTA throughout 2012-2015. The EUnetHTA Executive Committee monitors the implementation of the Work Plan and discusses if any prospective amendments need to be […]
WP5 Strand B – Procedure Manual V3
This document describes processes planned for conducting pilot rapid assessments for other technologies such as medical devices, surgical interventions or diagnostics. Since the Procedure Manual is a living document, further changes can be expected due to experiences gathered throughout JA2. Procedure Manual V3.pdf
EUnetHTA’s joint response to the public consultation on PAES_Amendments from IQWiG to HAS comments
Amendments_IQWiG_To_HAS_PAES joint response.pdf
Prognostic tests for breast cancer recurrence (PTBCR)
The three tests assessed in this core health technology assessment (HTA)— uPA/PAI-1 (FEMTELLE®, American Diagnostica) based on immunostaining techniques and MammaPrint® (Agendia) and Oncotype DX® (Genomic Health), based on gene expression profiling—measure multiple markers within the tumour that may indicate how the tumour is likely to develop. Agenas, Italy and SNHTA, Switzerland are the editors […]
External Initiatives Management Policy
This is the policy on the management of EUnetHTA’s involvement in external initiatives. EUnetHTA’s involvement in external initiatives_Policy
EUnetHTA Strategy 2012 and beyond
This document presents the EUnetHTA Strategy 2012 and beyond. Common interests and policies in relation to HTA have been explored and developed at the strategic level in the European Union for ten years. EUnetHTA (European network for HTA) has been a major platform for supporting this process, since its inception in 2006. Operating currently through […]
Technical Annex of the EUnetHTA JA2 Grant Agreement
Agreement will further present the target groups, the method and means and the expected outcome of the Joint Action 2 of EUnetHTA. The EUnetHTA Joint Action 2 Grant Agreement has been signed by the EU Executive Agency for Health and Consumers and the Coordinator (Danish Health and Medicines Authority) on behalf of 37 partners in […]
